- Home
- KROS
as 11-15-2024 4:00pm EST
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $91.43 | AVG Volume (30 days): | 383.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.31 - $73.00 | Next Earning Date: | 11-06-2024 |
| Revenue: | $651,000 | Revenue Growth: | 8037.50% |
| Revenue Growth (this year): | 1232.45% | Revenue Growth (next year): | 126.39% |
Latest Keros Therapeutics Inc. News
KROS Breaking Stock News: Dive into KROS Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
Keros Therapeutics Third Quarter 2024 Earnings: US$1.41 loss per share (vs US$1.33 loss in 3Q 2023)
GlobeNewswire
11 days ago
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
GlobeNewswire
11 days ago
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
GlobeNewswire
12 days ago
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition
MT Newswires
24 days ago
Cantor Fitzgerald Initiates Keros Therapeutics at Overweight
MT Newswires
a month ago
Scotiabank Initiates Keros Therapeutics at Sector Outperform
GlobeNewswire
a month ago
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer
MT Newswires
2 months ago
Guggenheim Initiates Keros Therapeutics at Buy With $96 Price Target
Compare KROS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KROS Keros Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.